Charles River Laboratories is generating robust free cash flow ($518M in FY2025) and trades at an EV/EBITDA discount to peers (13.2x vs. 17.2x median), suggesting the market is overly penalizing a non-cash-driven net loss. Operating income recovered to $508M from $227M in FY2024, and insider acquisitions of $16.5M net over 24 months signal board-level confidence, while a new CEO's strategic reset could unlock value. However, consecutive revenue declines (down to $4.02B from $4.13B in FY2023) and compressed gross margins (30.5% vs. 36.4% in FY2023) keep fundamentals in check, warranting a neutral stance until stabilization appears.
Persistent revenue contraction
Revenue declined again in FY2025 to $4.02B, extending a two-year downtrend; a prolonged biotech funding drought could deepen this.
Margin erosion and impairments
Gross margin fell from 36.4% in FY2023 to 30.5% in FY2025, and a $144M net loss in FY2025 hints at further non-cash charges that could recur.
Leveraging up
Total debt rose to $3.07B from $2.72B in FY2024, while equity shrank, pushing debt/equity to 0.97; higher rates or covenant pressure could constrain flexibility.
Strategic execution under new leadership
The recent CEO transition introduces uncertainty around the refreshed strategy; missteps in the GMP/CDMO partnerships could delay a turnaround.